Avery Dennison has extended its range of pharma anti-counterfeiting and anti-tampering products with the launch of Sharp Tear, designed for tamper-evident applications where an easy tear is required in the label.
The new product reveals tampering immediately by providing a seal that remains intact during normal handling, but which tears easily in one direction if attempts are made to open the package.
Sharp Tear is available in both exceptionally high clarity and very high opacity versions, to allow maximum flexibility across different packaging and product types.
It can either mask unwanted packaging information or allow important product details to be visible through the label.
According to Avery Dennison, the Sharp Tear label material also delivers high mandrel performance with long-term adhesion, and it comes with the regulatory compliance needed in pharma applications.
Productivity is also said to be improved, with a BG40 glassine release liner allowing conversion with conventional tooled dies, and the high adhesive coatweight “guaranteeing a true tamper evident feature”.
“The growth of internet sales, together with limited supplies of pharma products in some regions and significant price differentials, means that counterfeiting has become a very significant threat to all pharma brands,” says Hans Eichenwald, senior product manager Specialty Segments at Avery Dennison Materials Group.
“Today, around 10% of drugs sold are already counterfeit, according to the World Health Organization,” he adds.
“Sharp Tear offers a rapid and reliable way to secure both product safety and brand reputation without impacting productivity or product margins.”
Avery Dennison’s range of pharma anti-counterfeiting and anti-tampering products also includes customised UV-printed films and inserted UV threads, customised holograms and voids, and high-end taggants for ultimate security.
